Table 1.

SUVR results (Year 1) by titration regimen

Titration regimen	1	2	3	4	5	6	7
Study	SR	SR	SR	MR	MR	MR	MR
Last dose DB (mg)	0, 105	0, 105, 225	225	0, 105	225	0, 105	225
APOEε4 carrier	+	−	+	+	+	−	−
Number of individuals	n = 6	n = 2	n = 6	n = 19	n = 10	n = 10	n = 8
SUVRCFB%, mean predicted change based on planned OLE regimen	−12.2	−17.1	−17.1	−17.1	−18.9	−18.7	−19.7
SUVRCFB%, mean, (SD) predicted change based on dose received in OLE	−12.2 (1.6)	−10.3 (7.1)	−13.1 (1.1)	−12.3 (5.4)	−15.0 (2.5)	−16.6 (3.0)	−15.4 (3.4)
SUVRCFB%, mean (SD) observed in OLE	−9.2 (10.5)	−4.2 (6.3)	−12.7 (11.0)	−12.6 (9.0)	−16.3 (7.5)	−11.2 (9.0)	−14.8 (7.5)
Predicted vs. observed P value (paired t test)	0.56	0.64	0.93	0.90	0.68	0.13	0.82

APOEε4, apolipoprotein E ε4; DB, double‐blind period; MR, Marguerite RoAD; OLE, open‐label extension; PET, positron emission tomography; PK, pharmacokinetic; SD, standard deviation; SR, SCarlet RoAD; SUVR, standard uptake value ratio; SUVRCFB%, standard uptake value ratio percent change from baseline.